Boston Consulting Group

The Boston Consulting Group (BCG) is a global management consulting firm and the world’s leading advisor on business strategy. Now in our sixth decade, we continue not only to grow but also to embody the same timeless sense of purpose and the constant call for renewal that our founder Bruce Henderson instilled at our inception. Our mission is clear. We go deep to unlock insight and have the courage to act. We bring the right people together to challenge established thinking and drive transformation. We work with our clients to build the capabilities that enable organizations to achieve sustainable advantage. We are shaping the future.

HORTEN

Horten is a full-service law firm with more than 60 years’ experience and 320 employees, which is specialised within sectors characterised by strict regulation or where technological development and innovative approaches are fundamental – such as energy and supply, Life Science and Healthcare, IT, technology and media as well as the public sector.
We use our special expertise within regulated areas proactively to solve complex problems and think innovatively, be it new energy forms, advanced technology or cooperation between public and private parties.

Coloplast

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare. Our business includes Ostomy Care, Continence Care, Wound & Skin Care and Interventional Urology. We operate globally, and our organisation is about 11,000 people strong

HØIBERG

HØIBERG is a full service patent law firm located in Denmark, which is providing services within the fields of Intellectual Property Rights (IPR), including patents, designs, innovation management, technology transfer and business development. HØIBERG provides expert IPR knowledge in the fields ranging from biotech, medtech, nanotech, chemistry and cleantech to software, electronics and mechanics.

LEO Pharma

Leo Pharma is an independent, research-based pharmaceutical company. The company develops, manufactures and markets pharmaceutical drugs to dermatologic and thrombotic patients in more than 100 countries globally.

To realise their vision of becoming the preferred dermatology care partner improving people’s lives around the world, they are expanding into new regions and markets, reaching more patients and societies with drugs and therapies that address unmet medical needs.

Leo Pharma has its own sales forces in 61 countries and employs around 5,000 employees worldwide. The company is headquartered in Denmark and is wholly owned by the Leo Foundation.

Medicon Valley Alliance

MVA’s vision is to be a well-known and respected member-driven contributor to the realization and positioning of Medicon Valley as the most competitive and vital life science cluster in northern Europe. MVA is committed to realising the potential of Medicon Valley by facilitating networking and knowledge sharing, collaboration, analysing challenges and potentials, and mobilising support from key opinion leaders.

IDA

The Danish Society of Engineers, IDA – a modern professional association for technical, IT and natural sciences professionals.

IDA has more than 125.000 members and represents the interests of employees, managers and self-employed within the fields of pay and employment, the labour market, industrial policy, skills, careers and training, the working environment, technology and research.

IDA’s vision is to help technical knowledge workers set the agenda via competence development, network establishment, and political influence.

IDA’s goal is to be an influential, high profile society. Several politically appointed committees ensure that the views and objectives of our society become known and are made visible in areas ranging from education policy, equal opportunity, industrial and labour market policies, work environment and research and technology.

Novo Nordisk Regulatory Affairs

In Novo Nordisk, Regulatory Affairs secure the approval of new multi-billion dollar products and drug indications, making it possible for the company to bring innovative products to patients. The department stand at the centre of project planning and execution from the earliest stages of drug development all the way through life cycle management. A close collaboration with scientists to ensure new ideas will turn into successful products, thus a large part of Regulatory Affairs is based on the ability to understand the science behind.
The Regulatory Affairs graduate programme has been designed to develop top talents into becoming future leaders within this area. The Graduate Program is a two-year program consisting of three department rotations in which one of these will take place in one of the global affiliates. The Programme is open to applicants from all over the world who have recently acquired a degree from the life sciences such as pharmacy, chemical engineering, biology, biotechnology biomedicine or a related field.

Novo Nordisk Foundation

The Novo Nordisk Foundation is an independent Danish foundation with corporate interests. The Foundation has two objectives:
1) to provide a stable basis for the commercial and research activities of the companies in the Novo Group (Novo Nordisk A/S and Novozymes A/S)
2) to support scientific, humanitarian and social causes.

The history of the Foundation dates back to 1922, when Nobel Laureate August Krogh returned home to Denmark from Canada with permission to manufacture insulin in Scandinavia. This was the starting-point for developing world-class diabetes medicine and a Danish business and export venture. It also led to the establishment of several foundations that, many years later, merged into today’s Novo Nordisk Foundation.

The Novo Nordisk Foundation has supported Synapse with a three year grant.

 

Partners provide support for Synapse that helps us maintain our activities for students. Partners receive publicity and promotion through our channels.